Tissue Engineered Veins in Patients With Chronic Venous Insufficiency

This study aims to evaluate the safety (incidence of adverse events including serious adverse events and clinical significant laboratory abnormalities) of personalized tissue engineered veins (P-TEV) with valves implanted in patients with severe chronic venous insufficiency (CVI). For each patient a segment of the femoral vein containing the non-functioning valve will be surgically replaced with a single P-TEV containing a functioning valve.

Inclusion Criteria: * Patients aged between 18 and 75 years (inclusive) * CVI patients with painful swelling and/or skin changes and/or recurrent leg ulcer despite optimal conservative treatment for a period of time according to the investigator's judgement * Patients with deep venous reflux (grade 3 and above) * Meeting ASA (American Society of Anesthesiologists Classification) class 1 or 2 according to the PIs criteria * Laboratory values * INR \ 1,3) * Patients with thrombophilia according to the laboratory results at inclusion visit. One of the following criteria is needed for thrombophilia: Protein C \< 40% or Protein S \< 40 % or Leiden factor mutation or Antithrombin III \< 40 % or present Lupus anticoagulant or Homocysteine \> 1.5 ULN * Patients with an active infection requiring systemic antibiotic treatment * Patients with clinically significant cardiac disease (New York Heart Association, Class III or IV) or measured LVEF 40% * Patients with uncontrolled hypertension * Patients with renal dysfunction eGFR \< 45 ml/min (according to the MDRD calculation) * Patients with moderate or severe hepatic impairment (Child Pugh ≥ 7 points, i.e. class B or C) * Patients with ongoing immunosuppression, systemic Cortisol treatment etc. * Less than 3 months since previous ipsilateral venous intervention (e.g. Iliac recanalization) * Clinically significant iliocaval stenosis or occlusion * Current smoker of more than 20 cigarettes per day * Other uncontrolled intercurrent illness that would jeopardize the patient's safety, interfere with the objectives of the protocol, or limit the patient's compliance with study requirements, as determined by the Investigator in consultation with the Sponsor * Patients with severe SARSCoV-2 virus infection requiring hospitalization in the past 6 months